Search

Displaying results 6751 - 6760 of 7379 in total
  1. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  2. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  3. Drug

    Debamestrocel

    go.drugbank.com/drugs/DB17934
    Investigational

    Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]

  4. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand _ex vivo_.

    Synonyms: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo
  5. Drug

    Tesevatinib

    go.drugbank.com/drugs/DB11973
    Investigational

    In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

  6. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  7. Drug

    Ro 24-7429

    go.drugbank.com/drugs/DB16062
    Investigational

    Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).

  8. Drug

    BI 44370 TA

    go.drugbank.com/drugs/DB16037
    Investigational

    BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).

  9. Drug

    Cycloleucine

    go.drugbank.com/drugs/DB04620
    Experimental

    Cycloleucine is non-metabolisable amino acid formed by cyclization of leucine. It is also a specific and reversible inhibitor of nucleic acid methylation and widely used in biochemical experiments.

  10. Drug

    CDX-6512

    go.drugbank.com/drugs/DB17841
    Experimental

    Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]